Motus GI Holdings, Inc. (MOTS): Price and Financial Metrics


Motus GI Holdings, Inc. (MOTS)

Today's Latest Price: $1.51 USD

0.01 (-0.59%)

Updated Jan 28 11:14am

Add MOTS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 189 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

MOTS Stock Summary

  • MOTS's price/sales ratio is 304.39; that's higher than the P/S ratio of 98.16% of US stocks.
  • With a year-over-year growth in debt of 724.91%, Motus GI Holdings Inc's debt growth rate surpasses 97.49% of about US stocks.
  • Revenue growth over the past 12 months for Motus GI Holdings Inc comes in at 2,583.33%, a number that bests 99.63% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Motus GI Holdings Inc are OCX, ITCI, IPWR, FUV, and TRVN.
  • MOTS's SEC filings can be seen here. And to visit Motus GI Holdings Inc's official web site, go to www.motusgi.com.

MOTS Stock Price Chart Interactive Chart >

Price chart for MOTS

MOTS Price/Volume Stats

Current price $1.51 52-week high $2.30
Prev. close $1.52 52-week low $0.46
Day low $1.50 Volume 780,361
Day high $1.57 Avg. volume 3,846,516
50-day MA $1.08 Dividend yield N/A
200-day MA $1.08 Market Cap 48.72M

Motus GI Holdings, Inc. (MOTS) Company Bio


Motus GI Holdings, Inc., a development stage company, engages in developing single-use medical device systems in the United States. It is developing Pure-Vu system that integrates with existing colonoscopes to cleanse poorly prepped colons during the colonoscopy procedure. The company is based in Tirat Carmel, Israel.


MOTS Latest News Stream


Event/Time News Detail
Loading, please wait...

MOTS Latest Social Stream


Loading social stream, please wait...

View Full MOTS Social Stream

Latest MOTS News From Around the Web

Below are the latest news stories about Motus GI Holdings Inc that investors may wish to consider to help them evaluate MOTS as an investment opportunity.

Motus GI under pressure after $11M capital raise via warrant exercise

Motus GI ([[MOTS]] -14.7%) has signed a warrant exercise agreement with an existing institutional investor for potential gross proceeds of $11M.Under the agreement, the warrant holder agreed to exercise ~8M remaining private placement warrants of the ~8.7M that were originally issued in August 2020 at the stated exercise price of $1.30/share,...

Seeking Alpha | January 27, 2021

Perceptive Advisors Llc Sells 550,000 Shares of Motus GI Holdings, Inc. (NASDAQ:MOTS) Stock

Motus GI Holdings, Inc. (NASDAQ:MOTS) major shareholder Perceptive Advisors Llc sold 550,000 shares of the firm’s stock in a transaction on Friday, January 22nd. The stock was sold at an average price of $1.48, for a total value of $814,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which […]

Watchlist News | January 24, 2021

Motus GI's enhanced Pure-Vu system nabs European nod

DEKRA (EU Notified Body) has approved Motus GI's ([[MOTS]] +12.0%) enhancements to the Pure-Vu GEN2 System including software upgrades to increase the efficiency in cleansing the colon and enhanced ergonomics in loading and unloading the device on a colonoscope.The Pure-Vu System has received a CE Mark in the EU and...

Seeking Alpha | January 15, 2021

Motus GI Announces European Clearance of Enhanced Pure-Vu® GEN2 System to Harmonize with U.S. Configuration

Regulatory approval for enhanced system is a key milestone that supports evaluation of strategic partnership opportunities in the EU \- - - U.S. commercial rollout of Pure-Vu® GEN2 System enhancements initiated in Q4 2020FORT LAUDERDALE, Fla., Jan. 15, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today announced receiving approval from DEKRA (EU Notified Body) for enhancements to the Pure-Vu GEN2 System. The enhancements to the Pure-Vu GEN2 System were introduced to commercial customers in the U.S. during the fourth quarter of 2020.The enh...

Yahoo | January 15, 2021

Motus GI Announces Clinical Compendium of Pure-Vu System Patient Case Studies As Reported by Several Leading U.S. Hospitals

FORT LAUDERDALE, Fla., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that it has collected a series of case studies from several leading U.S. hospitals which highlight the advantages of utilizing its Pure-Vu System to successfully complete emergent or challenging colonoscopies for patients with inadequately prepared colons. The case studies are now available on the Motus GI website (click here). Tim Moran, chief executive officer of Motus GI, stated, "As we’ve expanded the number of commercial placements for the Pure...

Yahoo | December 16, 2020

Read More 'MOTS' Stories Here

MOTS Price Returns

1-mo 62.35%
3-mo 103.50%
6-mo 23.77%
1-year -27.75%
3-year N/A
5-year N/A
YTD 59.28%
2020 -58.60%
2019 -26.37%
2018 N/A
2017 N/A
2016 N/A

Continue Researching MOTS

Want to see what other sources are saying about Motus GI Holdings Inc's financials and stock price? Try the links below:

Motus GI Holdings Inc (MOTS) Stock Price | Nasdaq
Motus GI Holdings Inc (MOTS) Stock Quote, History and News - Yahoo Finance
Motus GI Holdings Inc (MOTS) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.9556 seconds.